BiotechTube

opioid receptor kappa antagonist

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Alcohol Dependence

Conditions

Alcohol Dependence

Trial Timeline

Dec 1, 2010 → Apr 1, 2011

NCT ID
NCT01232439

About opioid receptor kappa antagonist

opioid receptor kappa antagonist is a phase 1 stage product being developed by Eli Lilly for Alcohol Dependence. The current trial status is completed. This product is registered under clinical trial identifier NCT01232439. Target conditions include Alcohol Dependence.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT01232439Phase 1Completed

Competing Products

20 competing products in Alcohol Dependence

See all competitors
ProductCompanyStageHype Score
VK2809 + PlacebosViking TherapeuticsPhase 2
47
TERN-501 + TERN-101Terns PharmaceuticalsPhase 2
49
TERN-101Terns PharmaceuticalsPhase 2
49
TERN-201Terns PharmaceuticalsPhase 1
30
IVA337 + IVA337 + PlaceboInventivaPhase 2
47
LanifibranorInventivaPhase 2
47
IVA337 + Placebo + EmpagliflozinInventivaPhase 2
47
IVA337 + PlaceboInventivaPhase 3
72
LY686017 + PlaceboEli LillyPhase 2
52
LY3537031 + PlaceboEli LillyPhase 3
77
AD04 (ondansetron) + Matching placeboAdial PharmaceuticalsPhase 3
69
GODEX + PlaceboCelltrionPhase 3
77
Colesevelam HclDaiichi SankyoPhase 2
52
ASP9831 + PlaceboAstellas PharmaPhase 2
52
ASP8062 + PlaceboAstellas PharmaPhase 2
52
LY686017 + PlaceboEli LillyPhase 2
52
Mazdutide + PlaceboEli LillyPhase 2
52
Tirzepatide + PlaceboEli LillyPhase 2
52
LY2196044 + placeboEli LillyPhase 2
52
LY3537031 + PlaceboEli LillyPhase 3
77

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved
85
Olanzapine + PlaceboApproved
85
exenatide and sitagliptin + exenatide and placeboApproved
85
Tirzepatide + PlaceboApproved
85
tadalafilApproved
85